{
  "id": 14452918,
  "title": "Vir makes solid tumor T cell engager deal with Gilead",
  "url": "https://urgent.news/2026/10/14/vir-makes-solid-tumor-t-cell-engager-deal-with-gilead",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-14T12:30:21.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/vir-makes-solid-tumor-t-cell-engager-deal-with-gilead/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Vir Biotechnology and its CEO Marianne De Backer have notched yet another deal, this time with Gilead. Gilead will pay Vir $65 million upfront, with another $45 million in near-term milestones. Gilead's also paying a ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}